OKYO Pharma Limited

OKYO

$1.43

+$0.05 (3.62%)

Open

OKYO Pharma chairman Gabriele Cerrone buys 25,000 shares via Panetta Partners, lifts stake to 10,851,416 shares or 20.51% of capital

Loading chart...

IndexN/A

Market Cap0.06B

Enterprise Value0.05B

Income$-0.00B

Sales$0.00B

EmployeesN/A

P/E-28.69

P/SN/A

P/B-9.04

P/C-27.67

EV/EBITDA-6.86

EV/SalesN/A

EPS (ttm)-0.05

EarningsN/A

Gross Margin0.00%

Oper. Margin0.00%

Profit Margin0.00%

Volume0.05M

Shs Outstand0.04B

Change5.11%

Dividend Est.N/A

Dividend Ex-DateN/A

Perf YTDN/A

Perf YearN/A

Perf 3YN/A

Perf 5YN/A

Perf 10YN/A

IPON/A

Jul 1311:28AMDelta Air Lines earnings resilience supports valuation, Bank of America says(proactiveinvestors.com)09:27AMUS bank earnings could surprise to the upside as Bank of America highlights strong operating backdrop(proactiveinvestors.com)08:25AMFirst Hawaiian pushes into California with TriCo Bancshares deal(proactiveinvestors.com)05:50AMTSMC reports record June revenue, second quarter sales top guidance(proactiveinvestors.com)

Insider Trading

View All

Insider

Type

Price

Value

Date

Mantelli Flavio

—

187.5K

$1.96

$368K

Feb 10, 30

Denoyer Bernard

—

769

$2.13

$2K

Mar 14, 27

CERRONE GABRIELE M

Award

300.0K

$1.72

$516K

Jun 8, 26

Shah Keeren Rameshchandra

Award

40.0K

$1.85

$74K

Jun 8, 26

Simon Willy Jules

Award

6.5K

$1.85

$12K

Jun 8, 26

OKYO Pharma Limited is a biopharmaceutical firm operating at the preclinical stage, dedicated to developing innovative treatments for individuals in the United Kingdom experiencing inflammatory eye conditions and ocular discomfort. Its primary therapeutic candidate is OK-101, specifically designed to address dry eye disease. Additionally, the company is advancing OK-201, an experimental bovine adrenal medulla lipidated-peptide analogue, intended to treat neuropathic ocular pain. Established in 2007, OKYO Pharma Limited maintains its headquarters in London, UK.

CEO: Robert J. DempseyEmployees: 4www.okyopharma.com

Metric	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020	FY 2019	FY 2018
Revenue	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Cost of Revenue	$2.56K	$3.87K	$3.80K	$2.42K	$13.09K	$5.97K	$219.00	N/A
Gross Profit	$-2.56K	$-3.87K	$-3.80K	$-2.42K	$-13.09K	$-5.97K	$-219.00	N/A
Gross Margin	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Operating Expenses	$7.19M	$15.69M	$13.08M	$6.23M	$4.12M	$1.51M	$4.54M	$28.29M
Operating Income	$-7.19M	$-15.69M	$-13.09M	$-6.23M	$-4.13M	$-1.52M	$-4.54M	$-28.29M
Operating Margin	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Net Income	$-4.71M	$-16.83M	$-13.27M	$-5.43M	$-3.35M	$-1.54M	$-4.89M	$-28.30M
Net Margin	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
EPS (Basic)	$-0.12	$-0.00	$-0.60	$-0.36	$-0.32	$-0.17	$-0.62	$-4.80
EBITDA	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Stock Option Compensation Expense	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Price To Earnings Ratio	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Price To Sales Ratio	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Shares Outstanding	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Market Capitalization	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

OKYO Pharma Limited

Insider Trading

Discover more